PMN Stock Forecast & Price Target

ProMIS Neurosciences is attractive because PMN310 is designed to selectively neutralize toxic amyloid-beta oligomers while sparing plaque, a mechanism that could preserve efficacy and reduce the ARIA burden that has constrained approved anti-amyloid therapies. The PRECISE-AD Phase 1b study, with 144 patients enrolled, delivered a 6-month blinded interim showing zero ARIA-E across genotypes, placebo-like ARIA-H of 4.4%, and favorable biomarker movement including -15% pTau217 and -13.3% MTBR-tau243, while the company ended 2Q26 with about $53.4 million in cash and a net loss of $11.7 million. With PMN267 and PMN442 broadening the platform and the company funded through 2027, the positive view rests on a differentiated safety profile, clear target engagement, and the potential for substantially larger commercial uptake if the 1Q27 topline confirms clinical benefit.

ProMIS Neurosciences is a high-risk, single-lead story whose value depends heavily on PMN310, yet the program remains unvalidated in humans and must prove that selective Aβ oligomer targeting can deliver meaningful cognitive benefit without ARIA or other safety issues. The upcoming 1Q27 readout follows a Phase Ib study of only 140+ patients, far smaller than pivotal trials of >1,000 patients, making statistical significance on cognition difficult and leaving the program vulnerable to inconclusive biomarker and functional data. With Alzheimer’s programs large and costly and no cash flow yet, the company may need significant, potentially dilutive financing while competing against approved and well-resourced amyloid antibodies.